Carlyle Group Inc.Carlyle Group Inc.

Institutional investor · Portfolio as of Q2 2024

SEC EDGAR SourceSEC Filings

Top Holdings31 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction

QUIDELORTHO CORP

11.5M$382.7M36.3%$100.03-66.79%
9 qtrssince 2022-Q2
Decreased
0

ZOOMINFO TECHNOLOGIES INC

17.2M$220.2M20.9%$50.72-74.82%
17 qtrssince 2020-Q2
Decreased
0
SLNOSLNODelisted

SOLENO THERAPEUTICS INC

4.1M$166.4M15.8%$26.90+51.65%
6 qtrssince 2023-Q1
Unchanged
0
GDSGDS
ADR

GDS Holdings Ltd. Sponsored ADR Class A

4.1M$37.8M3.6%$20.58+71.94%
7 qtrssince 2022-Q4
Unchanged
0

PHATHOM PHARMACEUTICALS INC

3.5M$35.8M3.4%$7.87+30.80%
6 qtrssince 2023-Q1
Unchanged
0
VRNAVRNADelisted
ADR

VERONA PHARMA PLC

2.5M$35.5M3.4%
6 qtrssince 2023-Q1
Unchanged
0

GETTY IMAGES HOLDINGS INC

9.2M$30M2.9%$5.55-41.26%
7 qtrssince 2022-Q4
Unchanged
0
HLVXHLVXDelisted

HILLEVAX INC

1.8M$26.4M2.5%
6 qtrssince 2023-Q1
Unchanged
0

JASPER THERAPEUTICS INC

1.1M$24.2M2.3%$18.80+20.74%
6 qtrssince 2023-Q1
Unchanged
0

Q32 BIO INC

1.1M$19.2M1.8%$17.04+5.34%
2 qtrssince 2024-Q1
Unchanged
0

SEACOR MARINE HLDGS INC

1.3M$17.7M1.7%$10.73+25.69%
23 qtrssince 2018-Q4
Unchanged
0
INVHINVH
REIT

INVITATION HOMES INC

477,500$17.1M1.6%$27.70+22.60%
6 qtrssince 2023-Q1
Unchanged
0
CUBECUBE
REIT

CUBESMART

220,500$10M0.9%$33.47+23.93%
8 qtrssince 2022-Q3
Unchanged
0

SUNPOWER INC

4.9M$5.5M0.5%$1.39-19.39%
4 qtrssince 2023-Q3
Unchanged
0
2.7M$4.2M0.4%
6 qtrssince 2023-Q1
Unchanged
0
EMEMDelisted
ADR

SMART SH GLOBAL LTD

4.8M$4.1M0.4%$1.12-23.21%
9 qtrssince 2022-Q2
Unchanged
0

KRISPY KREME INC

340,748$3.7M0.3%$14.92-29.22%
2 qtrssince 2024-Q1
Unchanged
0
2.9M$3.6M0.3%
6 qtrssince 2023-Q1
Unchanged
0

SPRUCE BIOSCIENCES INC

2.9M$1.5M0.1%

AON PLC

4,973$1.5M0.1%$290.68+19.45%
1 qtr
New
43
$1.1B
AUM
31
Positions
Q2 2024
Filing
Rating · 1.5
Quarterly Portfolio Change
-2%Q1'23$3.4B-16%Q2'23$2.8B-18%Q3'23$2.3B-10%Q4'23$2.1B-24%Q1'24$1.6B-34%Q2'24$1.1B
Activity profile
$ moved · Q2'24
New0%Increased0%Decreased81%Exited19%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.5 years
<1Q3%1-4Q29%1-2Y35%2Y+32%

Carlyle Group Inc. manages $1.1B across 31 positions as of Q2 2024. Top holdings: QDEL (36.3%), GTM (20.9%), SLNO (15.8%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 1.5/5.0.

Q2 2024 Summary

Added 2 new positions, exited 3, trimmed 3. Top move: AON (NEW, conviction 43). Portfolio: $1.1B across 31 positions.

Top holdings by portfolio weight

Total AUM$1B
QDEL36.35%
GTM20.91%
SLNO15.80%
GDS3.59%
PHAT3.40%
VRNA3.37%
GETY2.85%
HLVX2.51%
JSPR2.30%
QTTB1.82%
Other1.68%

Portfolio allocation by GICS sector

Sectors9
Healthcare59.88%
Technology25.28%
Unknown6.74%
Communication Services2.85%
Real Estate2.57%
Industrials1.68%
Consumer Cyclical0.44%
Consumer Defensive0.35%
Financial Services0.21%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Healthcare, Technology
Compare DNA across all funds
7-dimension quality assessment
Below Average(1.5 / 5.0)
Track RecordNo data
Conviction38
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used